| 1 |
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013[J]. Heart Rhythm, 2013, 10(12):1932-1963.
|
| 2 |
Pappone C, Ciconte G, Vicedomini G, et al. Epicardial arrhythmogenic substrate in long QT syndrome[J]. Heart Rhythm, 2023, 20(12):1782-1784.
|
| 3 |
Dib Nehme R, Sinno L, Shouman W, et al. Cardiac channelopathies: clinical diagnosis and promising therapeutics[J]. J Am Heart Assoc, 2025, 14(9):e040072.
|
| 4 |
Begovic M, Schneider L, Zhou X, et al. The role of human-induced pluripotent stem cells in studying cardiac channelopathies[J]. Int J Mol Sci, 2024, 25(22):12034.
|
| 5 |
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4):663-676.
|
| 6 |
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J]. Cell, 2007, 131(5):861-872.
|
| 7 |
Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2[J]. Cell Stem Cell, 2009, 5(4):353-357.
|
| 8 |
Ye J, Boileau RM, Parchem RJ, et al. The miR-290 and miR-302 clusters are essential for reprogramming of fibroblasts to induced pluripotent stem cells[J]. Stem Cells, 2025, 43(2):sxae080.
|
| 9 |
Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells[J]. Proc Natl Acad Sci U S A, 2009, 106(37):15720-15725.
|
| 10 |
Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes[J]. Nat Biotechnol, 2008, 26(11):1276-1284.
|
| 11 |
Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells[J]. J Cell Sci, 2009, 122(Pt 19):3502-3510.
|
| 12 |
Kim J B, Greber B, Araúzo-Bravo MJ, et al. Direct reprogramming of human neural stem cells by OCT4[J]. Nature, 2009, 461(7264):649-643.
|
| 13 |
Guan J, Wang G, Wang J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells[J]. Nature, 2022, 605(7909):325-331.
|
| 14 |
Peng F, Wang Y, Cheng L, et al. Chemical reprogramming of human blood cells to pluripotent stem cells[J]. Cell Stem Cell, 2025, 32(8):1192-1199.e11.
|
| 15 |
Jiang X, Chen Y, Liu X, et al. Uncovering inherited cardiomyopathy with human induced pluripotent stem cells[J]. Front Cell Dev Biol, 2021, 9:672039.
|
| 16 |
Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes[J]. J Clin Invest, 2001, 108(3):407-414.
|
| 17 |
Guo NN, Liu LP, Zheng YW, et al. Inducing human induced pluripotent stem cell differentiation through embryoid bodies: a practical and stable approach[J]. World J Stem Cells, 2020, 12(1):25-34.
|
| 18 |
Mummery C, Ward-Van Oostwaard D, Doevendans P, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells[J]. Circulation, 2003, 107(21):2733-2740.
|
| 19 |
Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes[J]. Nat Methods, 2014, 11(8):855-860.
|
| 20 |
Kim JE, Kim EM, Lee HA, et al. Effective derivation of ventricular cardiomyocytes from hPSCs using ascorbic acid-containing maturation medium[J]. Anim Cells Syst (Seoul), 2023, 27(1):82-92.
|
| 21 |
Stiefbold M, Zhang H, Wan LQ. Engineered platforms for mimicking cardiac development and drug screening[J]. CellMol Life Sci, 2024, 81(1):197.
|
| 22 |
Ewoldt JK, Depalma SJ, Jewett ME, et al. Induced pluripotent stem cell-derived cardiomyocyte in vitro models: benchmarking progress and ongoing challenges[J]. Nat Methods, 2025, 22(1):24-40.
|
| 23 |
Neves R, Bains S, Bos JM, et al. Precision therapy in congenital long QT syndrome[J]. Trends Cardiovasc Med, 2024, 34(1):39-47.
|
| 24 |
Adler A, Novelli V, Amin AS, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome[J]. Circulation, 2020, 141(6):418-428.
|
| 25 |
Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome[J]. New Engl J Med, 2010, 363(15):1397-1409.
|
| 26 |
Ukachukwu CU, Jimenez-Vazquez EN, Salwi S, et al. A PAS-targeting hERG1 activator reduces arrhythmic events in Jervell and Lange-Nielsen syndrome patient-derived hiPSC-CMs[J]. JCI Insight, 2025, 10(4):e183444.
|
| 27 |
Louradour J, Hornyik T, De La Cruz A, et al. Beneficial action potential duration-shortening effects, but deleterious negative inotropism of IKs-activator docosahexaenoyl glycine in long QT syndrome type 2[J]. Europace, 2025, 27(9):euaf168.
|
| 28 |
Crotti L, Neves R, Dagradi F, et al. Therapeutic efficacy of mexiletine for long qt syndrome type 2: evidence from human induced pluripotent stem cell-derived cardiomyocytes, transgenic rabbits, and patients[J]. Circulation, 2024, 150(7):531-543.
|
| 29 |
Park YG, Park NK, Lee Y, et al. A machine learning platform for genotype-specific cardiotoxicity risk prediction using patient-derived iPSC-CMs[J]. J Adv Res, 2026, 82:381-396.
|
| 30 |
Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference[J]. Heart Rhythm, 2005, 2(4):429-440.
|
| 31 |
Hosseini SM, Kim R, Udupa S, et al. Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for brugada syndrome[J]. Circulation, 2018, 138(12):1195-1205.
|
| 32 |
Barc J, Tadros R, Glinge C, et al. Genome-wide association analyses identify novel Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility[J]. Nat Genet, 2022, 54(3):232-239.
|
| 33 |
Postema PG, Van Dessel PFHM, Kors JA, et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation[J]. J Am Coll Cardiol, 2010, 55(8):789-797.
|
| 34 |
Li Y, Lang S, Akin I, et al. Brugada syndrome: different experimental models and the role of human cardiomyocytes from induced pluripotent stem cells[J]. J Am Heart Assoc, 2022, 11(7):e024410.
|
| 35 |
Belbachir N, Portero V, Al Sayed ZR, et al. RRAD mutation causes electrical and cytoskeletal defects in cardiomyocytes derived from a familial case of Brugada syndrome[J]. Eur Heart J, 2019, 40(37):3081-3094.
|
| 36 |
Liang P, Sallam K, Wu H, et al. Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of brugada syndrome[J]. J Am Coll Cardiol, 2016, 68(19):2086-2096.
|
| 37 |
Sun Y, Su J, Wang X, et al. Patient-specific iPSC-derived cardiomyocytes reveal variable phenotypic severity of Brugada syndrome[J]. EBioMedicine, 2023, 95:104741.
|
| 38 |
Walsh R, Mauleekoonphairoj J, Mengarelli I, et al. A rare noncoding enhancer variant in SCN5A contributes to the high prevalence of brugada syndrome in thailand[J]. Circulation, 2025, 151(1):31-44.
|
| 39 |
Li Y, Rose L, Prädel T, et al. Phenotypes in Brugada syndrome with different genotypes triggered by fever or inflammation using gene-edited iPSCs[J]. Stem Cell Res Ther, 2025, 16:670.
|
| 40 |
Zhang X, Burattini M, Duru J, et al. Multimodal mapping of electrical and mechanical latency of human-induced pluripotent stem cell-derived cardiomyocyte layers[J]. ACS Nano, 2024, 18(35):24060-24075.
|
| 41 |
中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 2020室性心律失常中国专家共识（2016共识升级版）[J]. 中华心律失常学杂志, 2020, 24(3) :188-258.
|
| 42 |
Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave[J]. Circulation, 1996, 93(2):372-379.
|
| 43 |
Boukens BJ, Potse M, Coronel R. Fibrosis and conduction abnormalities as basis for overlap of brugada syndrome and early repolarization syndrome[J]. Int J Mol Sci, 2021, 22(4):1570.
|
| 44 |
Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge[J]. Europace, 2017, 19(4):665-694.
|
| 45 |
Treat JA, Pfeiffer R, Barajas-Martinez H, et al. Overlap arrhythmia syndromes resulting from multiple genetic variations studied in human induced pluripotent stem cell-derived cardiomyocytes[J]. Int J Mol Sci, 2021, 22(13):7108.
|
| 46 |
Wu Y, Kong XJ, Ji YY, et al. Correction of Ito in human induced pluripotent stem cell-derived cardiomyocyte carrying DPP6 mutation in early repolarization syndrome by CRISPR/Cas9 genome editing[J]. Exp Cell Res, 2024, 435(2):113929.
|
| 47 |
Pflaumer A, Davis AM. Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia[J]. Heart Lung Circ, 2012, 21(2):96-100.
|
| 48 |
Knollmann BC, Chopra N, Hlaing T, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia[J]. J Clin Invest, 2006, 116(9):2510-2520.
|
| 49 |
Schneider L, Begovic M, Zhou X, et al. Catecholaminergic polymorphic ventricular tachycardia: advancing from molecular insights to preclinical models[J]. J Am Heart Assoc, 2025, 14(6): e038308.
|
| 50 |
Gao J, Makiyama T, Yamamoto Y, et al. Novel calmodulin variant p.E46k associated with severe catecholaminergic polymorphic ventricular tachycardia produces robust arrhythmogenicity in human induced pluripotent stem cell-derived cardiomyocytes[J]. Circ Arrhythm Electrophysiol, 2023, 16(3):e011387.
|
| 51 |
Sander P, Feng M, Schweitzer MK, et al. Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca2+ uptake and suppress cardiac arrhythmogenesis[J]. Br J Pharmacol, 2021, 178(22):4518-4532.
|
| 52 |
Zhang XH, Donch GE, Yamaguchi N, et al. CPVT1 point mutations in RyR2 S5 and S6 segments and their Ca2+ signaling consequence[J]. Cell Calcium, 2025, 132:103081.
|
| 53 |
Stutzman MJ, Kim CSJ, Tester DJ, et al. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential[J]. Stem Cell Reports, 2022, 17(9):2023-2036.
|
| 54 |
Takaki T, Tamura N, Imahashi K, et al. Simultaneous optical recording of action potentials and calcium transients in cardiac single cells differentiated from type 1 CPVT-iPS cells[J]. Front Physiol, 2025, 16:1579815.
|
| 55 |
Dulak J, Zieliński T, Józkowicz A, et al. Pluripotent stem cell-based approaches for heart repair and the potential of genetic modifications[J]. Molecular Therapy, 2025, 33(10):4766-4783.
|
| 56 |
Begovic M, Schneider L, Zhou X, et al. The role of human-induced pluripotent stem cells in studying cardiac channelopathies[J]. Int J Mol Sci, 2024, 25(22):12034.
|
| 57 |
Bezzerides VJ, Caballero A, Wang S, et al. Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca2+/calmodulin-dependent kinase ii[J]. Circulation, 2019, 140(5):405-419.
|
| 58 |
Soldner F, Jaenisch R. Medicine. iPSC disease modeling[J]. Science, 2012, 338(6111):1155-1156.
|
| 59 |
Karbassi E, Fenix A, Marchiano S, et al. Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine[J]. Nat Rev Cardiol, 2020, 17(6):341-359.
|
| 60 |
Giacomelli E, Meraviglia V, Campostrini G, et al. Human-ipsc-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease[J]. Cell Stem Cell, 2020, 26(6):862-879.e11.
|
| 61 |
Lewis-Israeli YR, Wasserman AH, Gabalski MA, et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease[J]. Nat Commun, 2021, 12(1):5142.
|